We are cultivating a differentiated pipeline of small molecule medicines that utilize first-in-class or potential best-in-class mechanisms of action (MoAs) to restore balance in the brain by reducing the neuronal hyperexcitability that underlies debilitating brain conditions. Our unique understanding of the complexities of neurologic systems allows us to turn preclinical potential into clinical results.
Our aim is to make a meaningful impact and address the significant unmet need in the lives of individuals with neurological disorders that present with brain conditions.
Publications and Posters ยป
| Program/Indication |
Stage |
OV329, a next-generation GABA-aminotransferase inhibitor
|
|
GABA-aminotransferase inhibitor
Drug resistant adult focal onset seizures (FOS)
|
Phase 2
|
|
GABA-aminotransferase inhibitor
Drug resistant adult focal onset seizures (FOS)
|
Phase 2
|
|
GABA-aminotransferase inhibitor
Tuberous sclerosis complex seizures (TSC)
|
Phase 2
|
|
GABA-aminotransferase inhibitor
Infantile spasms (IS)
|
Phase 2
|
|
| Program/Indication |
Stage |
OV4071, Potassium-chloride cotransporter 2 (KCC2) direct activator (oral)
|
|
OV4071
Psychosis assoc. with Parkinson's disease and Lewy body dementia and acute schizophrenia
|
Phase 1
|
|
OV4071
Psychosis assoc. with Parkinson's disease and Lewy body dementia and acute schizophrenia
Ketamine challenge with biomarkers
|
Phase 1
|
*Timelines pending feedback from regulatory discussions Ketamine challenge to initiate pending PK characterization in Phase 1 study